Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Subscribe To Our Newsletter & Stay Updated
